Contents
Key findings
- 1GHK-Cu is a natural copper-binding tripeptide with well-documented effects on collagen synthesis, matrix remodelling and gene expression in laboratory systems.
- 2The best human evidence is for topical creams on photoaged skin — several small, short trials with improvements in fine lines, elasticity and photodamage; grade preliminary.
- 3Human wound-healing studies exist but are old, small and heterogeneous; animal wound data are stronger than human.
- 4Hair-growth claims rest on animal and cell studies. We could not find an adequately powered human trial with a validated hair-count endpoint.
- 5Injectable GHK-Cu, increasingly marketed for "systemic rejuvenation", has no human efficacy or safety data and is an unapproved drug.
Evidence level
Small human trials support modest effects of topical copper peptides on photoaged skin; wound-healing data are older and small; hair-growth and systemic claims rest on animal, cell and gene-expression studies. Most literature is authored by parties with commercial interests.
Regulatory status
Not FDA-approved as a drug. Permitted as a cosmetic ingredient (copper tripeptide-1). Injectable GHK-Cu is an unapproved drug; FDA placed it in category 2 of the compounding interim policies, and on the list current 22 April 2026 it appears among withdrawn nominations.
GHK-Cu is unusual among the peptides we cover: it is a natural human molecule, it has been in skincare for thirty years, and it has real, if small, human trials. It is also increasingly sold as an injectable "anti-aging" agent on the strength of laboratory gene-expression studies. Those are very different claims, and they deserve very different grades.
The question readers ask
Does GHK-Cu improve skin, regrow hair, or heal wounds? Split it into three: for topical skin use, small trials say modestly yes; for hair, no human trial has shown it; for wounds, animals yes, humans weakly and long ago. For injected GHK-Cu, there is no human evidence of anything.
What GHK-Cu is
GHK is a tripeptide — glycine, histidine, lysine — that binds copper avidly and circulates in human plasma at concentrations that fall several-fold between youth and old age. It was isolated in the 1970s and has since accumulated a large laboratory literature, much of it authored by its discoverer[1]. Mechanistically it is credible: GHK-Cu stimulates collagen and glycosaminoglycan production in fibroblasts, modulates matrix metalloproteinases and their inhibitors, promotes angiogenesis and nerve outgrowth in vitro, and — in a widely cited computational analysis — shifts gene-expression patterns in ways that resemble tissue-repair programs.
The mechanism is not in dispute. The question is what happens in people.
Skin: the best-evidenced claim
Several small randomised or controlled trials of copper peptide creams, typically 8–12 weeks in women with photoaged facial skin, report improvements in fine lines, elasticity, thickness and photodamage versus vehicle or a comparator cream[2]. Findings are reasonably consistent across studies. They are also small (tens of participants), short, use instrumental or investigator-rated endpoints, and were largely industry-supported; independent replication is thin.
That profile — real, replicated in small studies, not independent, not long — is what our preliminary grade means. Two comparators are worth keeping in mind: topical retinoids, which have decades of larger trials for photoaging, and the many other cosmetic peptides with less evidence than GHK-Cu.
Wound healing: stronger in animals than in people
GHK-Cu accelerates wound closure in rodent and other animal models, plausibly through the same matrix and angiogenic mechanisms. Human data are older and smaller: small studies in surgical and diabetic wounds from the 1990s and 2000s, with mixed quality and reporting[3]. Nothing approaches a modern adequately powered wound-healing trial, and no GHK-Cu product is approved for wound care.
Hair: an animal-and-cell claim wearing a human headline
The hair-growth story rests on GHK-Cu increasing hair follicle size in animal models and stimulating dermal papilla cells in culture, plus reasoning by analogy to minoxidil (both influence follicle blood supply). We could not find a randomised human trial with a validated hair-count or density endpoint. Until one exists this claim is preclinical. For a reader with hair loss, the practical point is that minoxidil and finasteride have the trials and approvals; GHK-Cu has a hypothesis.
"Gene resetting" and injectable GHK-Cu
The most striking GHK-Cu claim is that it "resets" gene expression toward a younger or healthier state, based on analyses matching GHK's in-vitro expression signature against a database of drug-induced signatures[1]. This is interesting computational biology. It is not evidence that injecting GHK-Cu into a person changes any tissue, symptom or outcome — and no such evidence exists.
Grades by claim
| Claim | Best human evidence | Grade |
|---|---|---|
| Improves photoaged skin (topical) | Several small controlled trials, 8–12 wks, mostly industry-linked | Preliminary evidenceSmall human trials |
| Accelerates wound healing | Old, small human studies; stronger animal data | Preliminary evidenceWeak human data |
| Promotes hair growth | None adequate; animal/cell only | Preclinical evidenceAnimal and in vitro |
| Systemic rejuvenation (injected) | None | Unsupported evidenceNo human data |
| Safe when injected | None | Unsupported evidenceNo human data |
Where to go next
- GHK-Cu profile — summary, FAQ and key studies.
- Skin and hair hub — GHK-Cu alongside collagen peptides.
- Collagen peptides: joint, skin and recovery evidence — the better-evidenced skin peptide.
Frequently asked questions
- Do copper peptide creams work?
- Small trials suggest modest improvements in photoaged skin over 8–12 weeks. The trials are short, small and mostly industry-linked, and topical retinoids remain the better-evidenced benchmark.
- Does GHK-Cu regrow hair?
- Not shown in humans. The evidence is animal and cell-based. Minoxidil and finasteride have the trial data; GHK-Cu does not.
- Is injecting GHK-Cu safe?
- Unknown — there are no controlled human data. Copper is biologically active, and injectable GHK-Cu is an unapproved drug that the FDA placed in category 2 of its compounding interim policies over immunogenicity concerns.
References
Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.
- 1.
Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data International Journal of Molecular Sciences, 2018.
Review
Result: Reviews GHK-Cu biology, gene-expression data (Broad Institute Connectivity Map analysis) and small clinical studies.
Limitations: Lead author discovered GHK-Cu and holds commercial interests.
↑ back to text - 2.
Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration BioMed Research International, 2015.
Review
Result: Summarises topical skin trials and mechanisms.
Limitations: Same author interests.
↑ back to text - 3.
Pickart L. The human tri-peptide GHK and tissue remodeling Journal of Biomaterials Science, Polymer Edition, 2008.
Review
Result: Reviews wound, hair-follicle and remodelling data, largely animal and in vitro.
Limitations: Author interests; older data.
↑ back to text - 4.
Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2 list) U.S. Food and Drug Administration, 2026.
Regulatory source
Result: GHK-Cu for injectable routes was placed in category 2 and now appears on the list of substances whose nominations were withdrawn by the nominators.
↑ back to text
Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.
